Clinical Trial Update: A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) [Phase 2]

View source ↗

Summary

Phase 2 trial ARIES evaluating rucaparib with nivolumab in selected solid tumors has been terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrioid Adenocarcinoma
• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• High Grade Serous Carcinoma
• Peritoneal Carcinoma

Drugs mentioned

• Rucaparib (rucaparib)
• nivolumab (nivolumab)

Snippet

Sponsor: pharmaand GmbH | Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-06-15